Christopher Penny - CAVA Group, Chief Officer
| CAVA Stock | 143.52 0.98 0.69% |
Executive
Christopher Penny is Chief Officer of CAVA Group,
| Age | 57 |
| Address | 14 Ridge Square NW, Washington, DC, United States, 20016 |
| Phone | 202 400 2920 |
| Web | https://www.cava.com |
CAVA Group, Management Efficiency
The company has return on total asset (ROA) of 0.0263 % which means that it generated a profit of $0.0263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0909 %, meaning that it created $0.0909 on every $100 dollars invested by stockholders. CAVA Group,'s management efficiency ratios could be used to measure how well CAVA Group, manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.01. The current year's Return On Capital Employed is expected to grow to 0.01. At present, CAVA Group,'s Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 2.7 M, whereas Total Assets are forecasted to decline to about 843.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jane Henderson | Apogee Therapeutics, Common | 58 | |
| Christian Taucher | Valneva SE ADR | N/A | |
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| Franck MBA | Valneva SE ADR | 57 | |
| Hagit Eliyahu | BOS Better Online | N/A | |
| Danny Lavi | BOS Better Online | N/A | |
| Wendy AspdenCurran | Apogee Therapeutics, Common | N/A | |
| Mehrak Kiankarimi | Apogee Therapeutics, Common | N/A | |
| MSc MD | Apogee Therapeutics, Common | N/A | |
| Dipal Patel | Valneva SE ADR | 49 | |
| Joshua Drumm | Valneva SE ADR | N/A | |
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| MSc MD | Centessa Pharmaceuticals PLC | 66 | |
| Dan Mulreany | Apogee Therapeutics, Common | N/A | |
| Susanne EderLingelbach | Valneva SE ADR | N/A | |
| Noel Kurdi | Apogee Therapeutics, Common | N/A | |
| Peter Buhler | Valneva SE ADR | 53 | |
| JuanCarlos MD | Valneva SE ADR | 52 | |
| Matthew JD | Apogee Therapeutics, Common | 48 | |
| Petra Pesendorfer | Valneva SE ADR | 38 | |
| Carl MD | Apogee Therapeutics, Common | 39 | |
Management Performance
| Return On Equity | 0.0909 | ||||
| Return On Asset | 0.0263 |
CAVA Group, Leadership Team
Elected by the shareholders, the CAVA Group,'s board of directors comprises two types of representatives: CAVA Group, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CAVA. The board's role is to monitor CAVA Group,'s management team and ensure that shareholders' interests are well served. CAVA Group,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CAVA Group,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tricia Tolivar, Chief Officer | ||
| Adam Phillips, Chief Officer | ||
| Andy Rebhun, Chief Officer | ||
| Theodore Xenohristos, Chief Director | ||
| Christopher Penny, Chief Officer | ||
| Jennifer Somers, Chief Officer | ||
| Brett Schulman, CEO, CoFounder | ||
| Robert Bertram, Chief Secretary | ||
| Beth McCormick, Chief Officer | ||
| Kelly Costanza, Chief Officer |
CAVA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CAVA Group, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0909 | ||||
| Return On Asset | 0.0263 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 16.33 B | ||||
| Shares Outstanding | 114.58 M | ||||
| Shares Owned By Insiders | 9.17 % | ||||
| Shares Owned By Institutions | 66.84 % | ||||
| Number Of Shares Shorted | 10.72 M | ||||
| Price To Book | 26.49 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CAVA Group, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CAVA Group,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cava Group, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cava Group, Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CAVA Group,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade CAVA Stock refer to our How to Trade CAVA Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Hotels, Restaurants & Leisure space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CAVA Group,. If investors know CAVA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CAVA Group, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.5 | Earnings Share 0.41 | Revenue Per Share 8.034 | Quarterly Revenue Growth 0.389 | Return On Assets 0.0263 |
The market value of CAVA Group, is measured differently than its book value, which is the value of CAVA that is recorded on the company's balance sheet. Investors also form their own opinion of CAVA Group,'s value that differs from its market value or its book value, called intrinsic value, which is CAVA Group,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CAVA Group,'s market value can be influenced by many factors that don't directly affect CAVA Group,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CAVA Group,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CAVA Group, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CAVA Group,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.